title: Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.
abstract: In 14 patients with cirrhosis and chronic portosystemic encephalopathy, the effectiveness of treatment with a new non-assorbable antibiotic (rifaximine) was compared to neomycin. The parameters evaluated were: bradylalia, flapping tremor, performance, visual evoked potentials and the trial making test. Both treatments were combined with lactulose. The analysis of results showed a rate of positive results in the patients treated with rifaximine greater than that with neomycin. Differences, however, were not significant.
authors.affiliation: Clinica Medica R Divisione di Medicina, Ospedale V Cervello, Universitì di Palermo, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Di Piazza
authors.forename: M
authors.initials: M
authors.lastname: Gabriella Filippazzo
authors.forename: L M
authors.initials: LM
authors.lastname: Valenza
authors.forename: S
authors.initials: S
authors.lastname: Morello
authors.forename: L
authors.initials: L
authors.lastname: Pastore
authors.forename: A
authors.initials: A
authors.lastname: Conti
authors.forename: S
authors.initials: S
authors.lastname: Cottone
authors.forename: L
authors.initials: L
authors.lastname: Pagliaro
mesh_terms: D002908:Chronic Disease; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use*; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
chemical_list: D012294:Rifamycins; D009355:Neomycin; D000078262:Rifaximin